Applied dna awarded contract by hdt bio for rapid vaccine development program

Award seeks to demonstrate feasibility of manufacturing mrna vaccines in only 7 days  stony brook, ny / accesswire / april 25, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, today announced the award of a contract from hdt bio for the purpose of rapid, next-generation vaccine development under a ‘project nextgen: enabler' award to hdt bio (the "project"). the project seeks to facilitate the rapid production of vaccines during outbreaks/pandemics, focusing on decentralized vaccine manufacturing, with vaccines deemed critical medical countermeasures to infectious disease threats.
APDN Ratings Summary
APDN Quant Ranking